JOHN GLENN - 07 Dec 2025 Form 4 Insider Report for IRADIMED CORP (IRMD)

Role: CHIEF FINANCIAL OFFICER
Signature: /s/ John Glenn
Issuer symbol: IRMD
Transactions as of: 07 Dec 2025
Transactions value $: -$1,101,741
Form type: 4
Filing time: 10 Dec 2025, 17:00:09 UTC
Previous filing: 12 Nov 2025
Next filing: 12 Dec 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
GLENN JOHN	CHIEF FINANCIAL OFFICER	C/O IRADIMED CORPORATION, 12705 INGENUITY DRIVE, ORLANDO	/s/ John Glenn	10 Dec 2025	0001253497

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	IRMD	Common Stock	Options Exercise		+10.5K	+420.16%		13K	07 Dec 2025	Direct	F1
transaction	IRMD	Common Stock	Tax liability	-$320K	-3.38K	-26.02%	$94.57	9.62K	07 Dec 2025	Direct
transaction	IRMD	Common Stock	Options Exercise		+21K	+218.36%		30.6K	07 Dec 2025	Direct	F2
transaction	IRMD	Common Stock	Tax liability	-$782K	-8.27K	-26.99%	$94.57	22.4K	07 Dec 2025	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	IRMD	Restricted Stock Units	Options Exercise	$0	-10.5K	-100%	$0.00	0	07 Dec 2025	Common Stock	10.5K		Direct	F1, F3
transaction	IRMD	Performance-based Restricted Stock Units	Options Exercise	$0	-21K	-100%	$0.00	0	07 Dec 2025	Common Stock	21K		Direct	F2, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Restricted stock units convert into common stock on a one-for-one basis.
F2	If the relative measure at December 7, 2025 and for the three-year period then ended is: (i) less than or equal to 80% of the peer group, no vesting would occur, (ii) between 80% and 100% of the peer group, the number of shares vesting would be pro-rata against the nominal granted shares, (iii) equal to 100% of the peer group, the number of shares vesting would be the nominal granted shares, (iv) between 100%and 120% of the peer group, the number of shares vesting would be pro-rata against an additional tranche of the nominal granted shares plus the nominal granted shares, and (v) if 120% or greater of the peer group, the number of shares vesting would be double the nominal granted shares.
F3	The reporting person received restricted stock units ("RSUs") under Iradimed Corporation's 2014 Equity Incentive Plan. The RSUs vest in full on the third anniversary of the grant date, December 7, 2025. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested.
F4	On December 7, 2022, the reporting person received performance-based restricted stock units ("PRSUs") under Iradimed Corporation's 2014 Equity Incentive Plan. Vesting of these PRSUs depends on the reporting person's achievement of specified relative ranking of total shareholder return over a three-year period from December 8, 2022 through December 7, 2025.